Added to YB: 2025-01-22
Pitch date: 2025-01-15
RCKT [bullish]
Rocket Pharmaceuticals, Inc.
-68.63%
current return
Author Info
No bio for this author
Company Info
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
Market Cap
$330.1M
Pitch Price
$10.87
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.56
P/E
-1.36
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Rocket Pharmaceuticals: A Rare Disease Opportunity with Robust Market Potential
RCKT: Gene therapy for Danon disease. Phase 1 data promising: increased LAMP2 expression, decreased heart size, improved NYHA class. Market: 7500-15000 patients, $9B+ potential revenue. Cash to 2027. Data expected late 2025/early 2026. Sector dumped, creating opportunity.
Read full article (2 min)